Helus' Psychedelic Depression Drug Succeeds in Phase 3 Trial But Faces Safety Scrutiny
According to Helus Pharma, its psychedelic drug candidate HLP003 significantly reduced major depression symptoms in a Phase 3 clinical trial. However, the study also recorded a number of serious adverse events, casting doubt on the overall safety of the treatment.

Original image temporarily unavailable
Helus Pharma announced that its psychedelic drug candidate, HLP003, showed positive results in a Phase 3 clinical trial for major depression. In the study, participants received one dose on the first day and a second dose three weeks later alongside standard antidepressants. At six weeks, the treatment group achieved a 19.5-point reduction on the MADRS depression rating scale, compared to an 11.9-point reduction in the placebo group. At 12 weeks, the effect was largely sustained, with a 16.9-point reduction for the treatment group versus 9.9 points for the placebo group, with all differences being statistically significant.
Despite the promising efficacy data, the trial recorded a number of serious adverse events. These safety concerns have raised questions regarding the risk-benefit profile of utilizing psychedelics for psychiatric conditions, a therapeutic avenue currently being explored by multiple companies in the biotechnology sector.
View selection rationale
Importance 73/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- STAT Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.

